Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800150 · ClinicalTrials.gov registry record · Phase 1
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
A Phase 1 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00800150 is a Phase 1 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT00800150, a Phase 1 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase I trial is studying the side effects and best dose of total marrow and total lymph node irradiation when given together with fludarabine and melphalan followed by donor stem cell transplant in treating patients with advanced hematological cancer that has not responded to treatment.
Interventions
- RADIATION intensity-modulated radiation therapy
- DRUG fludarabine phosphate
- DRUG melphalan
- PROCEDURE nonmyeloablative allogeneic hematopoietic stem cell transplantation
- RADIATION tomotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00800150
The ClinicalTrials.gov registry entry for NCT00800150 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which intensity-modulated radiation therapy is the first listed.
NCT00800150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00800150 about?
NCT00800150 is a clinical study titled "Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment". RATIONALE: Giving total marrow and total lymph node irradiation together with low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace th...
What is the current status of trial NCT00800150?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-11. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00800150?
The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), fludarabine phosphate (DRUG), melphalan (DRUG), nonmyeloablative allogeneic hematopoietic stem cell transplantation (PROCEDURE), tomotherapy (RADIATION).
Who is sponsoring clinical trial NCT00800150?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.